John Ebos


Research Interests:

Assessment of host and tumor contributions to efficacy and drug resistance following antiangiogenic and immune-checkpoint treatment Development of clinically relevant mouse models of advanced metastatic disease Discovery of biomarkers to aid in clinical optimization of VEGF and PD-1 pathway inhibitor use

About John Ebos


Dr. Ebos completed his undergraduate training at McGill University (B.Sc Biology; philosophy minor) and earned his Ph.D. in the Department of Medical Biophysics at the University of Toronto where he studied novel circulating molecules as potential surrogate markers of cancer progression and antiangiogenic drug efficacy.

Visit the Ebos Lab


Roswell Park Comprehensive Cancer Center
  • Associate Professor of Oncology
  • Department of Cancer Genetics and Genomics
  • Department of Medicine
  • Department of Pharmacology and Therapeutics (Graduate Program)


Education and Training:

  • PhD — Medical Biophysics, University of Toronto, Toronto, Canada
  • BSc — Biology, McGill University, Montreal, Canada


Research Overview:

Ebos Lab

Dr. Ebos’ laboratory currently focuses on the molecular mechanisms that drive intrinsic and acquired drug resistance to inhibitors of the tumor microenvironment and their impact on spontaneous metastatic disease. Of particular interest is the study of off-target ‘host’ effects following therapy that may alter disease progression and be exploited as biomarkers. The long-term goal of these efforts is pair novel experimental therapeutic testing in clinically relevant preclinical models with ongoing patient trials to more readily predict subsequent/alternative therapies to improve overall efficacy.

*Currently accepting MSc, PhD, and post-doctoral trainees

Featured on Cancer Talk


Full Publications list on PubMed